Camus V, Belot A, Oberic L, et al. - Among patients (pts) aged 60-80 yrs with previously untreated diffuse large B cell lymphoma (DLBCL) with age-adjusted IPI ≥1, who were enrolled in a multicentric, phase III, randomized trial (LNH03-6B trial), the efficacy of R-CHOP delivered every 2 weeks (R-CHOP14) or 3 weeks (R-CHOP21) with or without darbepoetin alfa was assessed, researchers conducted a prospective long-term follow-up (LTFU) program at close of this trial to assess long term (LT) results of these pts. In the LNH03-6B trial, 600 pts were randomized between December 2003 and December 2012. Number of patients intended to receive 8 cycles of R-CHOP14 or R-CHOP21 were 304 and 296 pts, respectively. Inquiry of LT outcomes data was done for 164/259 (63%) pts eligible to the LTFU program (lost to follow-up: n = 92, pts’ opposition: n = 3). According to findings, similar progression-free survival as well as overall survival, at 10 yrs post-randomization, were evident between groups. A very unfavorable prognosis resulted from progression, except for a small set of selected pts that underwent autologous stem cell transplant. There is a necessity of exploring new alternatives, including CAR-T cells therapy, as a second line treatment in this population.